Navigation Links
New perspectives on health disparities in breast cancer research
Date:11/28/2007

sons to reassess how African-American women are screened and treated for breast cancer. Our data suggests that although screening mammograms detect tumors of similar size, it appears that the advantage gained by early detection is relatively less in African-American women, Nichols said. This study merits further evaluation of whether African-American women would benefit from either more frequent mammograms or the use of more sensitive screening methods, such as MRI.

The University of Chicago study began in 1986 and, in the ensuing decades, encompassed 1,246 women, aged 40 and above, treated at University of Chicago Hospitals and affiliates. The women enrolled had either stage I or II cancer, and they were all treated by lumpectomy and radiotherapy. About one third of participants were African-American, and they were more likely to present with large tumors and cancer that was detectable in the lymph nodes. The researchers determined socioeconomic status by patients zip code and co-morbid diseases by patient report. Patients voluntarily defined their own ethnic status.

Nichols and his colleagues compared the African-American women to all other women enrolled in the study. When the researchers accounted for poverty and co-morbidity -- diseases such as hypertension, chronic pulmonary obstructive disease, coronary artery disease and diabetes -- race remained an independent trait that indicated poor prognosis for women with breast tumors detected through mammogram. Nichols cautioned that although the study controlled for many known prognostic indicators, it did not account for all. Our study did not include important known contributors including the status of the Her2 gene or detailed information regarding hormonal therapy, Nichols said.

Overall survival was worse for African-American women (78.1 percent versus 84.9 percent). In addition, disease-free survival, that is, survival without relapse eight years after treatment was also worse for A
'/>"/>

Contact: Greg Lester
greg.lester@aacr.org
267-646-0554
American Association for Cancer Research
Source:Eurekalert

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Brookings: Donor Perspectives on Innovative Financing for Global Health
2. Penn study finds pro-death proteins required to regulate healthy immune function
3. UCLA researchers identify markers that may predict diabetes in still-healthy people
4. Air pollution linked to cardiovascular risk indices in healthy young adults
5. More proof needed of safety and quality of electronic personal health records
6. Health care incentive model offers collaborative approach
7. Loneliness is bad for your health
8. Mailman School of Public Health study examines link between racial discrimination and substance use
9. Green Tea May Brew Up Healthier Skin
10. For Health Info, Women Often Turn to the Web
11. Record Number of Americans Lack Health Insurance
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Ascension Orthopedics Hires Key Senior Executives 2Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 2Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 3Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 4Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 5Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 6Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 4Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 5Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 6DIA 8th Annual Electronic Submissions Conference Addresses Current Developments in eCTD around the World 59225 1DIA 8th Annual Electronic Submissions Conference Addresses Current Developments in eCTD around the World 59225 2DIA 8th Annual Electronic Submissions Conference Addresses Current Developments in eCTD around the World 59225 3Gene Data Tool Advances Prospects for Personalized Medicine 59221 1Gene Data Tool Advances Prospects for Personalized Medicine 59221 2Gene Data Tool Advances Prospects for Personalized Medicine 59221 3Prize4Life Marks One Year Anniversary of Avi Kremer ALS Treatment Prize 59217 1Prize4Life Marks One Year Anniversary of Avi Kremer ALS Treatment Prize 59217 2Prize4Life Marks One Year Anniversary of Avi Kremer ALS Treatment Prize 59217 3